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Abstract
Background
Most patients managed in primary care have more
than one condition. Multimorbidity presents challenges
for the patient and the clinician, not only in terms of
the process of care, but also in terms of management
and risk assessment.
Aim
To examine the effect of the presence of chronic kidney
disease and diabetes on mortality and morbidity among




Random selection of 35 general practices in the west
of Ireland.
Method
A practice-based sample of 1609 patients with
established cardiovascular disease was generated in
2000–2001 and followed for 5 years. The primary
endpoint was death from any cause and the secondary
endpoint was a cardiovascular composite endpoint
that included death from a cardiovascular cause or any
of the following cardiovascular events: myocardial
infarction, heart failure, peripheral vascular disease, or
stroke.
Results
Risk of death from any cause was significantly increased
in patients with increased multimorbidity (P<0.001), as
was the risk of the cardiovascular composite endpoint
(P<0.001). Patients with cardiovascular disease and
diabetes had a similar survival pattern to those with
cardiovascular disease and chronic kidney disease, but
experienced more cardiovascular events.
Conclusion
Level of multimorbidity is an independent predictor of
prognosis among patients with established
cardiovascular disease. In such patients, the presence
of chronic kidney disease carries a similar mortality risk
to diabetes. Multimorbidity may be a useful factor in
prioritising management of patients in the community
with significant cardiovascular risk.
Keywords
chronic kidney disease; coronary disease; diabetes;
mortality; multimorbidity; primary care.
INTRODUCTION
There is a growing recognition in the literature that
multimorbidity — the simultaneous coexistence in
individuals of more than one disease state — is the rule
rather than the exception in primary care.1 A recent
editorial in the British Journal of General Practice
highlighted the many problems facing patients and
clinicians as a result of multimorbidity.2 Patients with
multimorbidity are more likely to die prematurely, be
admitted to hospital, have poor quality of life, and
experience a loss of physical functioning.3 With the
exception of relatively uncommon conditions, the
majority of visits to care for both an indicator condition
and any coexisiting conditions are made to primary
care physicians, not specialists.4
The practice of excluding patients with significant
multimorbidity from clinical trials contributes to a lack
of evidence with regard to appropriate interventions in
this group.5 The identification of trial participants
through acute settings, as well as the lack of reporting
of multimorbidity in those patients who are enrolled,6
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further limit the applicability of some research findings
to the primary care population that is heterogeneous
and multimorbid.7
Established cardiovascular disease, diabetes, and
chronic kidney disease are common and important
diagnoses in the community. These three conditions
have in common increased prevalence with age;
additionally, they often coexist and are responsible for
at least 40% of deaths in a developed country such as
Ireland. In patients with established cardiovascular
disease, diabetes is associated with a significantly
increased risk of cardiovascular mortality and
morbidity,8–11 as is chronic kidney disease.12–16
Previous reports have highlighted the importance of
improving the care of patients with diabetes or chronic
kidney disease alongside cardiovascular disease.11,12
However, there appears to be little evidence regarding
the relative and cumulative effect on prognosis of
cardiovascular multimorbidity (coexisting
cardiovascular disease and diabetes, and/or chronic
kidney disease).
Clarification of the extent to which cardiovascular
multimorbidity has a cumulative effect on risk, may
help to inform the development of cohesive
approaches to risk-factor management and improve
processes and outcomes of care. The current study
used a cohort of patients from a random sample of
practices with the full spectrum of cardiovascular
disease in the community. The study examined
whether a relationship exists between the level of




The methods by which the cohort was assembled
have been described previously.17,18 In short, the
study sample consisted of a cohort of 1609 patients
with cardiovascular disease, who were identified in
2000–2001 from a stratified random sample of 35
general practices in the west of Ireland. To generate
this sample, practices were randomly selected, after
stratification by practice type (single-handed or
group) and location (rural or urban), from the Health
Services Executive, Western Area and asked to
participate in the study.
After randomisation, 35 practices (60%) chose to
take part in the study; these were then asked to
generate a list of all their patients with established
cardiovascular disease using multiple methods,
including practice disease registers, patient
database searches, prescribing records, prospective
recording of patient attendance, and opportunistic
practitioner recall.
Patients were defined as having cardiovascular
disease if they had a history of myocardial infarction,
angina, or revacularisation by percutaneous coronary
intervention or coronary artery bypass grafting.
Patients were included in the current study where data
were available on diabetic status (written confirmation
of diagnosis of type 1 or type 2 diabetes, according to
World Health Organisation classification,19 from primary
or secondary care present at baseline in the medical
record) and kidney status (serum creatinine sample
measurement from the regional laboratory within the
study period or up to 30 days before recruitment).
Participants with positive and negative status for
diabetes and chronic kidney disease were part of the
study. However, if the researchers could not determine
whether participants were positive or negative, these
patients were not included. The first date of
measurement of serum creatinine was considered to
be the patient’s index date for purposes of analysis.
Follow-up data on the cohort were collected after a
period of 5 years; patients who had not died or
experienced a cardiovascular event were censored at
this point. Data on participants were also censored
where follow-up data ceased to be available.
Measurement of renal function
Renal function was assessed using estimated
glomerular filtration rate (GFR) calculated by the
abbreviated Modified Diet in Renal Disease (MDRD)
equation.20 Patients were defined as having chronic
kidney disease if they had an estimated GFR of
<60 ml/min/1.73 m2 according to National Kidney
Foundation guidelines:21
Estimated GFR (ml/min) = 186 × (serum creatinine
level in milligrams per deciliter) – 1.154 × (age in
years) – 0.203.
Sex and ethnicity data were collected at baseline to
determine the women and people of Afro-Caribbean
descent; the product of this equation was multiplied by
correction factors of 0.742 and 1.21 respectively.20
Outcomes
The primary endpoint was death from any cause.
How this fits in
Multimorbidity is the rule, rather than the exception, in primary care. Few
studies have compared outcomes for patients with varying levels of
cardiovascular multimorbidity. This study demonstrates that the level of
multimorbidity is an independent predictor of prognosis among patients with
established cardiovascular disease. These data also suggest that, in patients
with cardiovascular disease, diabetes carries a similar mortality risk to chronic
kidney disease but is associated with a higher incidence of cardiovascular
events. Multimorbidity may be a useful indicator when it comes to prioritising
the management of patients with chronic disease in the community.
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over the study period, while controlling for all
explanatory variables. Adjusted hazard ratios,
categorised according to level of multimorbidity in
instances of death from any cause and the
cardiovascular composite endpoint, were determined
while adjusting for all other significant explanatory
variables.
Assumptions underlying the final models were
checked using suitable residual plots, and the
interactions between multimorbidity and the key
categorical variables, such as sex, smoking status, and
previous myocardial infarction, were investigated. All
statistical test values were two-sided, and a P-value of
less than 0.05 was considered to indicate statistical
significance. Analysis was carried out using SPSS
(version 14.0) and R statistical software.
RESULTS
Baseline characteristics
Among the original 1609 patients in the study, 42
(2.6%) patients were lost to follow up and 1256
(78.1%) had complete data on level of multimorbidity
and follow up. Median follow up was 2.9 years
(standard deviation 1.47) and there were no significant
differences in age, sex, social status, smoking status,
diabetes status, and previous cardiovascular morbidity
between patients with and without complete datasets.
Mortality data were collected from a search of practice
records and the General Register Office: the central
civil repository for records relating to births, marriages,
and deaths in the Republic of Ireland. The secondary
endpoint was a cardiovascular composite endpoint
that included death from a cardiovascular cause
(included as either a primary or a contributing factor
according to the death certificate, but not if simply a
coexisting morbidity),22 or any of the following
cardiovascular events: myocardial infarction, heart
failure, peripheral vascular disease, and stroke.
Statistical analysis
For analysis of baseline characteristics and survival
analysis, patients were classified according to level of
multimorbidity. Baseline characteristics were analysed
with the use of one-way analysis of variance for
continuous variables and a χ2-test for categorical
variables. Patient variables included 18 baseline
characteristics (Table 1).
To control for the large number of covariates,
variable selection techniques were used to identify the
most succinct model containing significant explanatory
variables, while including the covariate of interest (level
of multimorbidity). Cox proportional hazards models
(backwards elimination, Wald criterion) were used to
evaluate the prognostic effect of level of multimorbidity
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CVD only CVD and CKD CVD and diabetes CVD and diabetes
Characteristic (n = 718) (n = 388) (n = 81) and CKD (n = 69)
Mean age in years 68.6 74.9 68.8 74.8
Female, % 24.5 54.1 25.6 50.7
Current smoker, % 32.4 26.6 28.4 19.0
Previous CVD event, %
Myocardial infarction 48.0 43.7 46.9 39.7
Angina 84.6 87.6 86.4 85.3
Heart failure 5.3 8.1 3.7 14.5
Previous CVD intervention, %
Coronary artery bypass graft 19.1 17.8 22.0 24.6
Percutaneous coronary intervention 16.1 10.5 12.2 10.3
Previous comorbidity, %
Peripheral vascular disease 3.9 5.3 14.6 15.9
Stroke 3.0 5.6 9.8 8.7
Thromboembolism: PE, DVT, TIA 9.3 14.7 7.3 14.5
Baseline clinical status, mean (SD)
Systolic blood pressure, mmHg 137.5 (18.1) 139.8 (20.2) 142.3 (18.6) 143.9 (22.0)
Diastolic blood pressure, mmHg 80.9 (9.8) 80.3 (8.6) 82.9 (8.1) 80.6 (8.6)
Total cholesterol, mmol/L 5.3 (1.0) 5.5 (1.1) 5.1 (1.2) 5.3 (1.1)
Baseline medication, %
Aspirin 75.7 71.9 81.7 72.5
Beta-blocker 48.9 46.8 35.4 39.1
Lipid-lowering agent 51.3 44.5 53.7 50.7
ACE inhibitor 23.6 24.3 43.9 43.5
aTotal number of patients = 1256. ACE = angiotensin-converting enzyme. CKD = chronic kidney disease. CVD = cardiovascular
disease. DVT = deep vein thrombosis. PE = pulmonary embolism. TIA = transient ischemic attack.
Table 1. Baseline characteristics of patients with cardiovascular disease according
to level of cardiovascular multimorbidity.a
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Level of cardiovascular multimorbidity Total, n Number of events (%) Censored, n (%)
CVD only 718 53 (7.4) 665 (92.6)
CVD and CKD 388 55 (14.2) 333 (85.8)
CVD and diabetes 81 12 (14.8) 69 (85.2)
CVD, CKD, and diabetes 69 21 (30.4) 48 (69.6)
Total 1256 141 (11.2) 1115 (88.8)
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Level of cardiovascular multimorbidity  Total, n Number of events (%) Censored, n (%)
CVD only 718 68 (9.5) 650 (90.5)
CVD and CKD 388 61 (15.7) 327 (84.3)
CVD and diabetes 81 15 (18.5) 66 (81.5)
CVD, CKD, and diabetes 69 23 (33.3) 46 (66.7)
Total 1256 167 (13.3) 1089 (86.7)
CKD = chronic kidney disease. CVD = cardiovascular disease.
Figure 1. Kaplan-Meier survival plots for risk of ‘death from any cause’ according to level of
cardiovascular multimorbidity.
Figure 2. Kaplan-Meier survival plots for risk of composite cardiovascular outcome
according to level of cardiovascular multimorbidity.
Table 1 details the baseline characteristics of the
patients according to level of multimorbidity. A total
of 718 (57.2%) patients had cardiovascular disease
only; 388 (30.9%) had cardiovascular disease and
chronic kidney disease; 81 (6.4%) had
cardiovascular disease and diabetes; and 69 (5.5%)
patients had cardiovascular disease, chronic kidney
disease, and diabetes.
Compared with other patients in the study, patients
with multimorbidity involving all three conditions had a
higher prevalence of heart failure and peripheral
vascular disease; and had a higher mean systolic
blood pressure.
Outcomes
During follow up there were 141 deaths and 167
cardiovascular events. The risk of death from any
cause (log-rank/Mantel-Cox 42.24, P<0.001) was
significantly increased in patients with increased level
of multimorbidity (Figure 1) as was the risk of the
cardiovascular composite endpoint (log-rank/Mantel-
Cox 38.56, P<0.001; Figure 2).
In the examination of the relationship between the
primary and secondary outcomes and level of
multimorbidity while controlling for all significant
explanatory variables, patients with cardiovascular
disease only were used as the reference group (Table
2). The explanatory variables available for inclusion in
the Cox proportional hazards model were age, sex,
smoking status, systolic blood pressure, diastolic
blood pressure, total cholesterol level, previous
myocardial infarction, angina, heart failure, stroke,
peripheral vascular disease, thromboembolic events,
prior percutaneous coronary intervention, prior
coronary artery bypass grafting, and medication use.
The adjusted hazard ratios for both outcomes
according to level of multimorbidity are given in Table
2. Estimated risk of death from any cause (primary
endpoint), when compared with patients with
cardiovascular disease only, was 1.82 (95%
confidence interval [CI] = 1.11 to 2.99) for patients with
cardiovascular disease and chronic kidney disease;
1.73 (95% CI = 0.79 to 3.78) for patients with
cardiovascular disease and diabetes; and 4.73 (95% CI
= 2.43 to 9.18) for patients with all three conditions.
Estimated risk of the cardiovascular composite
(secondary endpoint), when compared with patients
with cardiovascular disease only, was 1.35 (95% CI =
0.88 to 2.07) for patients with cardiovascular disease
and chronic kidney disease; as compared with 2.29
(95% CI = 1.25 to 4.17) for patients with cardiovascular
disease and diabetes; and 2.72 (95% CI = 1.54 to 4.81)
for patients with all three conditions. No significant
two-way interactions were identified between
multimorbidity and other factors in the model when
considering death by any cause.
Comparison with existing literature
Reported prevalence of cardiovascular
multimorbidity in this study population is probably an
underestimation, particularly in light of the lower-
than-expected proportion of patients with diabetes
compared with other populations.23,24 Population
surveys suggest that 30% of adults suffer from more
than one chronic health problem.25 In the US, the
prevalence of multimorbidity is estimated at 65% in
those over 65 years of age.26 There is a large
discrepancy between the prevalence of
multimorbidity in the general population and the
number of research studies devoted to it, especially
in primary care.5
Following myocardial infarction, diabetes and
chronic kidney disease appear to predict mortality
and increased adverse outcomes. In patients with
previous myocardial infarction, the incidence of
death from a cardiovascular cause is 42% among
those with diabetes compared with 15.9% among
those who do not have diabetes.11 The 1-year
mortality of older patients with moderate chronic
kidney disease (serum creatinine 220–343 mol/L)
after myocardial infarction is nearly tripled compared
with those with normal renal function (66% versus
24%).27 The evidence in this study suggests that this
risk is not confined to patients with previous
myocardial infarction, but exists in all patients with
cardiovascular disease.
Strengths and limitations of the study
This study had a number of limitations. Although the
hypothesis was formulated before starting analyses,
data collection was retrospective. In addition, the
cohort was not formed as a de novo population with
multimorbidity. Instead, this was a cardiovascular
population in which multimorbidity was then identified.
Although the level of multimorbidity appears to
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There was evidence of a significant interaction
between multimorbidity and previous myocardial
infarction (P = 0.009) when modeling the
cardiovascular composite endpoint. This interaction
appears to represent an increased risk of
experiencing a composite event for those patients
with cardiovascular disease and diabetes who have
had a previous myocardial infarction, when
compared with the effect of previous myocardial
infarction in the other multimorbidity categories.
DISCUSSION
Summary of main findings
Multimorbidity is common in this representative
community-based population of patients with
cardiovascular disease, with 43% of patients
having chronic kidney disease or diabetes or both.
Multimorbidity appears to be a significant risk
factor for mortality and for new cardiovascular
morbidity. Patients with cardiovascular disease and
diabetes appear to have a similar risk of death to
those with cardiovascular disease and chronic
kidney disease but experienced more
cardiovascular events. For patients with
cardiovascular disease, chronic kidney disease,
and diabetes, mortality and morbidity appeared to
be significantly and independently increased above
the risk associated with the addition of chronic
kidney disease or diabetes alone.
The effect of cardiovascular multimorbidity
appears more marked on all-cause mortality than
the composite cardiovascular endpoint used in
this study. It is likely that those patients with
increasing cardiovascular multimorbidity also had
increasing levels of multimorbidity generally. This,
coupled with the increased associated
polypharmacy, would contribute to a risk profile that
is generally poorer.
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Level of cardiovascular Primary endpoint: Secondary endpoint:
multimorbidity death from any cause cardiovascular composite
ß̂ expß̂ (95% CI) ß̂ expß̂ (95% CI)
CVD onlyb – 1.00 – 1.00
CVD and CKD 0.598 1.82 (1.11 to 2.99) 0.299 1.35 (0.88 to 2.07)
CVD and diabetes 0.550 1.73 (0.79 to 3.78) 0.827 2.29 (1.25 to 4.17)
CVD, CKD, and diabetes 1.553 4.73 (2.43 to 9.18) 1.001 2.72 (1.54 to 4.81)
Total number of patients = 1256. aCox proportional hazards model used in the above analysis adjusted for the following
covariates (*denotes covariates kept in the final all-cause mortality model; **denotes covariates kept in the final
cardiovascular composite event model): age*,**; sex; smoking status*; systolic blood pressure; diastolic blood pressure;
total cholesterol level**; previous myocardial infarction**; angina; heart failure; stroke; peripheral vascular disease**;
thromboembolic events; prior percutaneous coronary intervention; prior coronary artery bypass grafting; use of aspirin;
beta-blocker; lipid-lowering agent; or ACE (angiotensin converting enzyme) inhibitor*,**.
bThis group served as the reference group. CVD = cardiovascular disease. CKD = chronic kidney disease.
Table 2. Adjusted hazard ratios for primary and secondary endpoints among
patients according to level of cardiovascular multimorbidity.a
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discriminate prognosis between patients with
established cardiovascular disease, it is difficult to
identify the different elements of this association, as
chronic kidney disease can have its origin in
cardiovascular disease and diabetes.
Another limitation was that the study sample was
Caucasian and the prevalence of diabetes and chronic
kidney disease in this study may underestimate the
prevalence in other ethnic groups. Further, the
proportion of patients with diabetes (11.9%) is less
than that reported in other relevant studies.23,24 This
study was unable to ascertain cases of impaired
glucose tolerance or impaired fasting glucose in the
cohort studied — this reflects the current lack of
proactive diagnosis of diabetes in primary care in the
Republic of Ireland. It is likely that the true impact of
diabetes and dysglycemia on mortality in the current
cohort has been underestimated.
Finally, lack of availability of serum creatinine data
in the community setting excluded some patients
from the study and shortened follow up in others.
This reflects the limited availability of data, which can
restrict chronic-disease management and research
in primary care.
To the authors’ knowledge, this is the first
description of the comparative risks associated with
diabetes and chronic kidney disease in a
cardiovascular population in primary care. This study
describes a nationally representative community-
based cohort of patients with cardiovascular disease.
To the extent that this was possible, the cohort
comprised the total populations with cardiovascular
disease of a randomly selected sample of practices.
Despite the difficulties of detailed data collection in
primary care, very few patients were lost to follow up.
Implications for future research and clinical
practice
To date, clinical management and practice guidelines
are based on evidence from disease-specific
research efforts focusing on a single condition, rather
than taking into account multimorbidity which is
experienced by most patients.28,29 Payment for
performance in primary care, based on adherence to
disease-specific guidelines, is being considered in a
number of other countries around the world and has
been accepted in the UK with the Quality and
Outcomes Framework. There is a method within this
system whereby patients who are thought to be
unsuitable for application of a disease-specific
guideline can be excluded, for example, where there
exists a contraindication, a supervening condition,
terminal illness, or frailty. It is hoped that such
exclusions are limited, appropriate, and have no
adverse effect on the care of individual patients.
However, the lack of evidence-based guidance on
493
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best practice for instances where comorbidity
excludes a patient from a guideline is unfortunate,
given the overwhelming prevalence of such patients
in primary care. This absence of national, or
international, guidelines for the management of
patients with multimorbidity highlights the gulf that
exists between the complexity of disease and the
reductionism inherent in disease-specific guideline
development.
As chronic-disease management moves
increasingly to primary care, there are
understandable concerns regarding associated
workload. It has been suggested that multimorbidity
affects the majority of patients in primary care and
the current results suggest that such multimorbidity
may become a useful tool to prioritise their disease
management. A mortality rate of over 30% over a
3-year period for those with cardiovascular
multimorbidity (coexisting cardiovascular disease,
diabetes, and chronic kidney disease in this study) is
striking, albeit among a small subgroup of 69
patients from 35 practices. It is unfortunate that
analysis of comorbidity is not possible using UK
Quality and Outcomes Framework data as a result of
data being collected at an aggregate level from each
practice.
As the number of patients with multimorbidity
continues to rise, the need to develop strategies that
may improve their survival, physical functioning, and
quality of life becomes increasingly important. A
paucity of experimental data in this area undermines
the development of guidance on management of this
complex patient group. The current data suggest
that, although those with coexisting cardiovascular
disease, diabetes, and chronic kidney disease are
clearly a group at high risk of death and
cardiovascular events, risk-factor management
remains suboptimal. Such results highlight a
potentially vital role for primary-care physicians in
risk-factor assessment and management decision-
making for patients with multimorbidity — whether
such a role will lead to improved outcomes requires
further experimental work.
Level of multimorbidity appears to discriminate
prognosis among patients with established
cardiovascular disease. The current data suggest that
in patients with cardiovascular disease, diabetes
carries a similar mortality risk to chronic kidney
disease, but is associated with a higher incidence of
cardiovascular disease events.
Multimorbidity may be a useful tool to prioritise the
management of patients with chronic disease in the
community, a concept that may be of particular
interest in light of the planned focus on the
prevention and management of chronic disease by
the World Health Organisation.30 To develop effective
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management strategies, innovative approaches to
the study of this population are required and,
because of the diversity of patients and medical
conditions encountered, primary care offers an ideal
setting for this to take place.
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